Pfizer Inc. (NYSE:PFE) Shares Acquired by Private Advisor Group LLC

Private Advisor Group LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 15.4% during the third quarter, Holdings Channel reports. The firm owned 849,585 shares of the biopharmaceutical company’s stock after acquiring an additional 113,623 shares during the quarter. Private Advisor Group LLC’s holdings in Pfizer were worth $24,587,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer in the 2nd quarter valued at about $29,000. Quarry LP acquired a new position in Pfizer in the 2nd quarter valued at about $31,000. Trivant Custom Portfolio Group LLC increased its position in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the 2nd quarter valued at about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $28.85 on Wednesday. The business’s 50 day simple moving average is $29.07 and its 200-day simple moving average is $28.48. The firm has a market capitalization of $163.46 billion, a price-to-earnings ratio of -62.71, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. Pfizer’s dividend payout ratio is currently -365.21%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PFE. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Thursday, October 3rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.